New Trends in Brain Shuttle Peptides
View/Open
This document contains embargoed files until 2026-03-03
Other authors
Publication date
2025-03-03ISSN
1543-8392
Abstract
The pharmacological treatment of central nervous system diseases faces significant challenges due to the presence of the blood–brain barrier (BBB). This barrier naturally protects the brain and prevents therapeutics from reaching their targets efficiently. However, the BBB allows the passage of nutrients and other molecules that guarantee brain homeostasis through selective transport mechanisms present at the BBB. These mechanisms provide an opportunity for delivering therapeutic agents into the central nervous system using brain shuttles. Here we review the progress of brain shuttle peptide development from 2015 until 2025. We highlight the most utilized peptides and describe trends in strategies to develop new shuttles and enhance their transport efficiency. Additionally, we compared them with other types of brain shuttles and emphasize the progress of peptide shuttles toward clinical translation.
Document Type
Article
Document version
Accepted version
Language
English
Subject (CDU)
615 - Pharmacology. Therapeutics. Toxicology
616.1 - Pathology of the circulatory system, blood vessels. Cardiovascular complaints
Keywords
Blood-brain barrier
Brain shuttle
Drug delivery
Peptide shuttle
Central nervous system therapeutics
Barrera hematoencefàlica
Medicaments--Modes d'administració
Sistema nerviós central--Tractament
Pages
p.10
Publisher
American Chemical Society
Is part of
Molecular Pharmaceutics 2025, 22, 3, 1100–1109
Grant agreement number
info:eu-repo/grantAgreement/MCIU/PN I+D/PID2023-151988OB-I00
This item appears in the following Collection(s)
Rights
© L'autor/a